What's new in the diagnosis and pathophysiology of thrombotic thrombocytopenic purpura

Hematology (United States)

Volumn 2015, Issue 1, 2015, Pages 631-636

  Sadler, J Evan ^a,b  

^a Departments of Medicine and Biochemistry   (United States)

^b WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

VON WILLEBRAND FACTOR CLEAVING PROTEINASE; ADAM PROTEIN; ADAMTS13 PROTEIN, HUMAN; VON WILLEBRAND FACTOR;

ARTERY THROMBOSIS; ARTICLE; CLINICAL FEATURE; ENZYME ASSAY; ENZYME DEFICIENCY; HEMOLYSIS; HEMOLYTIC ANEMIA; HUMAN; HYPERBILIRUBINEMIA; KIDNEY FAILURE; LIVER FAILURE; MULTIPLE ORGAN FAILURE; NEUROLOGIC DISEASE; PATHOPHYSIOLOGY; SEPSIS; THROMBOCYTOPENIA; THROMBOTIC THROMBOCYTOPENIC PURPURA; VEIN THROMBOSIS; VENOUS THROMBOEMBOLISM; ARTERY; BLOOD; COMPLICATION; DEFICIENCY; HEMATOLOGY; METABOLISM; PATHOLOGY; PROCEDURES; PURPURA, THROMBOTIC THROMBOCYTOPENIC; THROMBOSIS; TRENDS;

ADAM PROTEINS; ADAMTS13 PROTEIN; ARTERIES; HEMATOLOGY; HEMOLYSIS; HUMANS; NERVOUS SYSTEM DISEASES; PURPURA, THROMBOTIC THROMBOCYTOPENIC; RENAL INSUFFICIENCY; THROMBOSIS; VENOUS THROMBOSIS; VON WILLEBRAND FACTOR;

EID: 85011004210     PISSN: 15204391     EISSN: 15204383     Source Type: Journal    
DOI: 10.1182/asheducation-2015.1.631     Document Type: Article

References (41)

1. Sadler JE. Von Willebrand factor, ADAMTS13, and thrombotic thrombocytopenic purpura. Blood. 2008;112(1):11-18.
2. Coppo P, Schwarzinger M, Buffet M, et al. Predictive features of severe acquired ADAMTS13 deficiency in idiopathic thrombotic microangiopathies: the FrenchTMAreference center experience. PLoS One. 2010;5(4): e10208.
3. Kremer Hovinga JA, Vesely SK, Terrell DR, Lammle B, George JN. Survival and relapse in patients with thrombotic thrombocytopenic purpura. Blood. 2010;115(8):1500-1511.
4. Terrell DR, Motto DG, Kremer Hovinga JA, Lammle B, George JN, Vesely SK. Blood group O and black race are independent risk factors for thrombotic thrombocytopenic purpura associated with severe ADAMTS13 deficiency. Transfusion. 2011;51(10):2237-2243.
5. George JN, Nester CM. Syndromes of thrombotic microangiopathy. N Engl J Med. 2014;371(7):654-666.
6. Zafrani L, Mariotte E, Darmon M, et al. Acute renal failure is prevalent in patients with thrombotic thrombocytopenic purpura associated with low plasma ADAMTS13 activity. J Thromb Haemost. 2015;13(3):380-389.
7. Loirat C, Coppo P, Veyradier A. Thrombotic thrombocytopenic purpura in children. Curr Opin Pediatr. 2013;25(2):216-224.
8. Sellier-Leclerc AL, Fremeaux-Bacchi V, Dragon-Durey MA, et al. Differential impact of complement mutations on clinical characteristics in atypical hemolytic uremic syndrome. J Am Soc Nephrol. 2007;18(8): 2392-2400.
9. Fremeaux-Bacchi V, Fakhouri F, Garnier A, et al. Genetics and outcome of atypical hemolytic uremic syndrome: a nationwide French series comparing children and adults. Clin J Am Soc Nephrol. 2013;8(4):554-562.
10. Noris M, Caprioli J, Bresin E, et al. Relative role of genetic complement abnormalities in sporadic and familial aHUS and their impact on clinical phenotype. Clin J Am Soc Nephrol. 2010;5(10):1844-1859.
11. Braune SA, Wichmann D, von Heinz MC, et al. Clinical features of critically ill patients with Shiga toxin-induced hemolytic uremic syndrome. Crit Care Med. 2013;41(7):1702-1710.
12. Takanashi J, Taneichi H, Misaki T, et al. Clinical and radiologic features of encephalopathy during 2011 E coli O111 outbreak in Japan. Neurology. 2014;82(7):564-572.
13. Imanirad I, Rajasekhar A, Zumberg M. A case series of atypical presentations of thrombotic thrombocytopenic purpura. J Clin Apher. 2012;27(4):221-226.
14. Htun KT, Davis AK. Neurological symptoms as the sole presentation of relapsed thrombotic thrombocytopenic purpura without microangiopathic haemolytic anaemia. Thromb Haemost. 2014;112(4):838-840.
15. Idowu M, Reddy P. Atypical thrombotic thrombocytopenic purpura in a middle-aged woman who presented with a recurrent stroke. Am J Hematol. 2013;88(3):237-239.
16. Rojas JC, Banerjee C, Siddiqui F, Nourbakhsh B, Powell CM. Pearls and oy-sters: acute ischemic stroke caused by atypical thrombotic thrombocytopenic purpura. Neurology. 2013;80(22):e235-e238.
17. Sevy A, Doche E, Squarcioni C, et al. Stroke in a young patient treated by alteplase heralding an acquired thrombotic thrombocytopenic purpura. J Clin Apher. 2011;26(3):152-155.
18. Camous L, Veyradier A, Darmon M, et al. Macrovascular thrombosis in critically ill patients with thrombotic micro-angiopathies. Intern Emerg Med. 2014;9(3):267-272.
19. Kelly PJ, McDonald CT, Neill GO, Thomas C, Niles J, Rordorf G. Middle cerebral artery main stem thrombosis in two siblings with familial thrombotic thrombocytopenic purpura. Neurology. 1998;50(4): 1157-1160.
20. Yarranton H, Cohen H, Pavord SR, Benjamin S, Hagger D, Machin SJ. Venous thromboembolism associated with the management of acute thrombotic thrombocytopenic purpura. Br J Haematol. 2003;121(5):778-785.
21. Bennett M, Chubar Y, Gavish I, Aviv A, Stemer G, Chap-Marshak D. Experiences in a family with the Upshaw-Schulman syndrome over a 44-year period. Clin Appl Thromb Hemost. 2014;20(3):296-303.
22. Kokame K, Nobe Y, Kokubo Y, Okayama A, Miyata T. FRETSVWF73, a first fluorogenic substrate for ADAMTS13 assay. Br J Haematol. 2005;129(1):93-100.
23. Kato S, Matsumoto M, Matsuyama T, Isonishi A, Hiura H, Fujimura Y. Novel monoclonal antibody-based enzyme immunoassay for determining plasma levels of ADAMTS13 activity. Transfusion. 2006;46(8):1444-1452.
24. Hubbard AR, Heath AB, Kremer Hovinga JA; Subcommittee on von Willebrand F. Establishment of the WHO 1st International Standard ADAMTS13, plasma (12/252): communication from the SSC of the ISTH. J Thromb Haemost. 2015;13(6):1151-1153.
25. Raval JS, Padmanabhan A, Kremer Hovinga JA, Kiss JE. Development of a clinically significant ADAMTS13 inhibitor in a patient with hereditary thrombotic thrombocytopenic purpura. Am J Hematol. 2015; 90(1):E22.
26. Rieger M, Mannucci PM, Kremer Hovinga JA, et al. ADAMTS13 autoantibodies in patients with thrombotic microangiopathies and other immunomediated diseases. Blood. 2005;106(4):1262-1267.
27. Froehlich-Zahnd R, George JN, Vesely SK, et al. Evidence for a role of anti-ADAMTS13 autoantibodies despite normal ADAMTS13 activity in recurrent thrombotic thrombocytopenic purpura. Haematologica. 2012;97(2):297-303.
28. Muia J, Gao W, Haberichter SL, et al. An optimized fluorogenic ADAMTS13 assay with increased sensitivity for the investigation of patients with thrombotic thrombocytopenic purpura. J Thromb Haemost. 2013;11(8):1511-1518.
29. Barber BE, William T, Grigg MJ, et al. Parasite biomass-related inflammation, endothelial activation, microvascular dysfunction and disease severity in vivax malaria. PLoS Pathog. 2015;11(1):e1004558.
30. Lowenberg EC, Charunwatthana P, Cohen S, et al. Severe malaria is associated with a deficiency of von Willebrand factor cleaving protease, ADAMTS13. Thromb Haemost. 2010;103(1):181-187.
31. Colombatti R, De Bon E, Bertomoro A, et al. Coagulation activation in children with sickle cell disease is associated with cerebral small vessel vasculopathy. PLoS One. 2013;8(10):e78801.
32. Meyer SC, Sulzer I, Lammle B, Kremer Hovinga JA. Hyperbilirubinemia interferes with ADAMTS-13 activity measurement by FRETSVWF73 assay: diagnostic relevance in patients suffering from acute thrombotic microangiopathies. J Thromb Haemost. 2007;5(4):866-867.
33. Lu RN, Yang S, Wu HM, Zheng XL. Unconjugated bilirubin inhibits proteolytic cleavage of von Willebrand factor by ADAMTS13 protease. J Thromb Haemost. 2015;13(6):1064-1072.
34. Uemura M, Fujimura Y, Matsumoto M, et al. Comprehensive analysis of ADAMTS13 in patients with liver cirrhosis. Thromb Haemost. 2008;99(6):1019-1029.
35. Pereboom IT, Adelmeijer J, van Leeuwen Y, Hendriks HG, Porte RJ, Lisman T. Development of a severe von Willebrand factor/ADAMTS13 dysbalance during orthotopic liver transplantation. Am J Transplant. 2009;9(5):1189-1196.
36. Ono T, Mimuro J, Madoiwa S, et al. Severe secondary deficiency of von Willebrand factor-cleaving protease (ADAMTS13) in patients with sepsis-induced disseminated intravascular coagulation: its correlation with development of renal failure. Blood. 2006;107(2):528-534.
37. Nguyen TC, Han YY, Kiss JE, et al. Intensive plasma exchange increases a disintegrin and metalloprotease with thrombospondin motifs-13 activity and reverses organ dysfunction in children with thrombocytopenia-associated multiple organ failure. Crit Care Med. 2008;36(10): 2878-2887.
38. Peigne V, Azoulay E, Coquet I, et al. The prognostic value of ADAMTS13 (a disintegrin and metalloprotease with thrombospondin type 1 repeats, member 13) deficiency in septic shock patients involves interleukin-6 and is not dependent on disseminated intravascular coagulation. Crit Care. 2013;17(6):R273.
39. Kremer Hovinga JA, Zeerleder S, Kessler P, et al. ADAMTS-13, von Willebrand factor and related parameters in severe sepsis and septic shock. J Thromb Haemost. 2007;5(11):2284-2290.
40. Hyseni A, Kemperman H, de Lange DW, Kesecioglu J, de Groot PG, Roest M. Active von Willebrand factor predicts 28-day mortality in patients with systemic inflammatory response syndrome. Blood. 2014; 123(14):2153-2156.
41. Wu N, Liu J, Yang S, et al. Diagnostic and prognostic values of ADAMTS13 activity measured during daily plasma exchange therapy in patients with acquired thrombotic thrombocytopenic purpura. Transfusion. 2015;55(1):18-24.